subject area of
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults Journal Articles
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome Journal Articles
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients Journal Articles
- Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial Journal Articles
- Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study Journal Articles
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol Journal Articles
- Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis Journal Articles
- PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations Journal Articles
- PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis Journal Articles
- Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 Journal Articles
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes Journal Articles
- Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis Journal Articles
- Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Journal Articles